CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Short Interest Up 229.0% in June

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) was the target of a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 1,311,363 shares, a growth of 229.0% from the June 15th total of 398,648 shares. Based on an average daily volume of 559,861 shares, the days-to-cover ratio is presently 2.3 days. Approximately 3.2% of the shares of the stock are sold short.

CAMP4 Therapeutics Price Performance

Shares of CAMP opened at $4.33 on Monday. The stock has a market cap of $224.84 million, a PE ratio of -1.83 and a beta of 0.10. CAMP4 Therapeutics has a 12-month low of $1.32 and a 12-month high of $7.75. The business has a 50-day simple moving average of $4.26 and a two-hundred day simple moving average of $4.61.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.11). The firm had revenue of $1.29 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. On average, equities research analysts expect that CAMP4 Therapeutics will post -0.84 EPS for the current year.

Wall Street Analysts Forecast Growth

CAMP has been the topic of a number of analyst reports. Leerink Partners increased their price objective on shares of CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a research note on Thursday, April 2nd. Rodman & Renshaw assumed coverage on shares of CAMP4 Therapeutics in a research report on Tuesday, April 14th. They issued a “buy” rating and a $7.00 target price for the company. Chardan Capital set a $6.50 price target on shares of CAMP4 Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 10th. JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. Finally, Weiss Ratings cut shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $8.36.

Institutional Investors Weigh In On CAMP4 Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE bought a new stake in CAMP4 Therapeutics during the 4th quarter worth approximately $86,000. Bridgeway Capital Management LLC bought a new position in shares of CAMP4 Therapeutics during the second quarter valued at $36,000. Two Sigma Investments LP bought a new position in shares of CAMP4 Therapeutics during the third quarter valued at $292,000. Vivo Capital LLC acquired a new position in shares of CAMP4 Therapeutics during the third quarter worth $11,765,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of CAMP4 Therapeutics in the fourth quarter worth $61,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.